Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149099 | 0.91 | KDM4E (0.55) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7039193 | 0.90 | LMNA (0.61) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7145859 | 0.89 | JAK2 (0.54) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7145623 | 0.88 | LMNA (0.48) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7151579 | 0.84 | LMNA (0.46) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7143968 | 0.82 | LMNA (0.47) | LMNAMAPTJAK2KDM4ESMN1; SMN2 | |
| SCHEMBL6870164 | 0.82 | KDM4E (0.58) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7140763 | 0.81 | MAPT (0.68) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7767039 | 0.80 | SMN1; SMN2 (0.46) | LMNAMAPTPDE4DJAK2KDM4E | |
| SCHEMBL7041685 | 0.80 | GABRD (0.47) | LMNAMAPTKDM4EPARP15TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |